|Dr. Friedhelm Blobel Ph.D.||Chief Exec. Officer, Pres and Exec. Director||1.17M||9.57M||68|
|Mr. Wilson W. Cheung||Chief Financial Officer and Sr. VP of Fin.||799.97k||612.96k||48|
|Mr. Hong Zhao||Chief Exec. Officer of China Operations||935.79k||N/A||54|
|Ms. Lan Xie||VP of Fin. and Chief Financial Officer of China Operations||494.9k||137.51k||44|
|Mr. Carey Chern||Chief Compliance Officer, Gen. Counsel and Corp. Sec.||N/A||N/A||50|
SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, provides therapies for oncology, infectious diseases, and cardiovascular disorders in the Peoples Republic of China, the United States, and Hong Kong. Its lead product is ZADAXIN, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as an immune system enhancer. In addition, the company focuses on developing ZADAXIN for the treatment of sepsis. SciClone Pharmaceuticals, Inc. markets and sells ZADAXIN through distribution arrangements, local importers, and distributors. It also markets and distributes products, such as DC Bead, Holoxan, Mesna, Endoxan, Methotrexate, Estracyt, Farlutal, Neucardin, Angiomax, and Cleviprex. The company has a strategic partnership with The Medicines Company to promote Angiomax (bivalirudin) and Cleviprex (clevidipine). SciClone Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Foster City, California.
SciClone Pharmaceuticals, Inc.’s ISS Governance QualityScore as of June 2, 2017 is 1. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 1; Compensation: 4.